On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

The technology is genuinely useful for scientific discovery, but its applications are less dramatic than you might think.

A scientific revolution is underway as researchers push to bring atomic-level precision, once reserved for small molecule ...

Moderna (NasdaqGS:MRNA) experienced a 10% share price increase, coinciding with broader market gains but slightly below the Nasdaq Composite's 5% rise. Despite the market being uplifted by strong ...

mRNA vaccines offer clear advantages and disadvantages ... candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. Sanofi is developing ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

The H5N1 avian influenza virus, first detected in humans ... with the U.S. allocating 500 million USD to pharmaceutical companies for mRNA-based vaccine development. Lessons from the COVID-19 ...

The H5N1 avian influenza virus, first detected in humans ... with the U.S. allocating 500 million USD to pharmaceutical companies for mRNA-based vaccine development. Lessons from the COVID-19 ...

With some mRNA approaches also using AI to personalise each vaccine to the patient, there are also questions about how to regulate a product that can differ each time it is delivered. As such ...

For decades, expanding into foreign markets meant making a major investment in physical presence – setting up local offices ...

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that ...